Curevo Vaccine Revenue and Competitors

Seattle, WA USA

Location

#4750

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Curevo Vaccine's estimated annual revenue is currently $7.8M per year.(i)
  • Curevo Vaccine's estimated revenue per employee is $155,000

Employee Data

  • Curevo Vaccine has 50 Employees.(i)
  • Curevo Vaccine grew their employee count by 35% last year.

Curevo Vaccine's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CFOReveal Email/Phone
3
CMOReveal Email/Phone
4
Director Clinical OperationsReveal Email/Phone
5
Associate Director Clinical OperationsReveal Email/Phone
6
Associate Director Quality CMCReveal Email/Phone
7
Director OperationsReveal Email/Phone
8
Director, ImmunologyReveal Email/Phone
9
Director Clinical DevelopmentReveal Email/Phone
10
Assoc. Director Program Mgmt.Reveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$5.1M336%N/AN/A
#4
$5.7M3742%N/AN/A
#5
$1.4M18-10%N/AN/A
#6
$3.7M48-21%$16MN/A
#7
$1.1M70%N/AN/A
#8
$0.8M5-81%N/AN/A
#9
$2.5M16-27%N/AN/A
#10
$0.8M5-17%N/AN/A
Add Company

What Is Curevo Vaccine?

Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development. Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available. Curevo’s goal is to rapidly advance innovative new vaccine candidates from research laboratory to clinic by joining forces with South Korean Mogam Institute for Biomedical Research, GC Pharma, and the Infectious Disease Research Institute based in Seattle, Washington.

keywords:N/A

N/A

Total Funding

50

Number of Employees

$7.8M

Revenue (est)

35%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6M500%N/A
#2
$8.8M5028%N/A
#3
$5.8M50N/AN/A
#4
$8.6M50-12%N/A
#5
$7.6M506%N/A